echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and Development Daily treats type 2 diabetes Lilly Trulicity has added two new high-dose labels

    Research and Development Daily treats type 2 diabetes Lilly Trulicity has added two new high-dose labels

    • Last Update: 2020-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.09.04 Research and Development NEWS: Failed phase III trial of vadadustat III chronic kidney disease anemia in Akebia, FDA approves first automated "artificial pancreas" for early childhood patients, and Abivax oral anti-inflammatory drug treatment of ulcerative colitis phase IIa trial is successful... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original article) Akebia Therapeutics announced the results of a phase III cardiovascular program trial, PRO2TECT, just days before the failure of Akebia's Phase III trial of vadadustat III.
    results show that the trial reached the main therapeutic end, but missed the safe end.
    Abivax oral anti-inflammatory drug treatment of ulcerative colitis phase IIa trial success recently, Abivax company published ABX464 treatment ulcerative colitis (UC) phase IIa study of 2 years maintenance treatment data.
    the study group, previously insatiable and/or difficult to treat at least one existing treatment.
    2-year maintenance treatment showed that 69% of patients received clinical remission and 94% benefited from clinical response.
    drug approved the addition of two new high-dose labels to Lilly Trulicity for type 2 diabetes, the FDA approved two additional doses of Lilly Trulicity (dulaglutide, saccharide peptide).
    this approval expanded trulicity's weekly allergy label by 3.0 mg and 4.5 mg doses, mainly based on positive results from the AWARD-11 study.
    Dongju Pharmaceutical biosychic drug TAB008 declared on the market 4th, Dongzhu Pharmaceuticals announced that the State Drug Administration has officially accepted the Bayval Pearl single anti-biosychable drug TAB008 (commodity name: Park Xintin®, English name: Pusintin) listing application.
    TAB008 is the first biopharmace product to be submitted for listing in Dong'an Pharmaceuticals' fully autonomous development project, which is a milestone for Dong's own business development.
    the FDA approved Medtron's MiniMed 770G system for the first automated "artificial pancreas" FDA for early childhood patients.
    This is the first hybrid closed-loop diabetes management device approved for use in people aged 2 to 6 with type 1 diabetes, which automatically monitors blood sugar and automatically adjusts insulin administration based on the value of continuous blood sugar monitoring.
    Conning Jerry PD-L1/CTLA-4 dual-specific antibody was approved by the FDA orphan drug 3, Corning Jerry announced that its self-developed recombinant humanized PD-L1/CTLA-4 dual-specific antibody KN046 was awarded by the FDA orphan drug qualification for the treatment of thymus epitheliote tumors.
    this is Corninger's second orphan drug qualification since the injection of PD-L1 monolithic antibody KN035 earlier this year was approved by the FDA as an orphan drug for bile pathogenic cancer.
    health yuan inhalation with isopropyl tobly bromide solution products obtained the drug registration certificate 4, health yuan issued a notice that the company received the State Drug Administration approved the issuance of the "drug registration certificate."
    In accordance with the Drug Administration Law of the People's Republic of China and the relevant provisions, after examination, the solution of isopropyl tobly bromide for inhalation of healthy yuan meets the relevant requirements of drug registration, approves registration and issues a drug registration certificate.
    Modern Pharmaceutical subsidiary Catopley tablet review 4, Hyundai Pharmaceuticals announced that the company's wholly-owned subsidiary, State Pharmaceutical Goldstone recently received the State Drug Administration approved the issuance of The Catopri tablet "Drug Supplemental Application Approval Notice", approved the drug through generic drug quality and efficacy consistent evaluation.
    to Ling Pharmaceutical Lianhua Qing plague capsules to obtain the Kuwaiti drug registration certificate 4, Toling Pharmaceuticals issued a notice that recently, the company received the Kuwaiti Drug and Plant Medicine Registration and Control Department approved the issuance of drug registration approval documents, approved the company's pharmaceutical Lianhua Qing plague capsules in line with the Kuwaiti plant medicine product standard registration.
    Research and Development Cooperation: Sanofi/GSK New Crown Vaccine Start-up Human Clinical Trial Phase 3 trials are expected to begin by the end of the year Today, Sanofi and GlaxoSmithKline jointly announced that the COVID-19 ad adhesive vaccine jointly developed by the two companies to start Phase 1/2 clinical trials.
    the vaccine candidate uses the same recombinant protein vaccine technology as one of Sanofi's approved seasonal flu vaccines, as well as GSK's proven pandemic vaccine adversanide technology.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.